We are live on ! Find out more
SRTA

Strata Critical Medical Inc

122 hedge funds and large institutions have $184M invested in Strata Critical Medical Inc in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 41 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

365% more call options, than puts

Call options by funds: $1.63M | Put options by funds: $351K

52% more capital invested

Capital invested by funds: $121M → $184M (+$63M)

24% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 17

21% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 34

2.52% more ownership

Funds ownership: 52.85%55.37% (+2.5%)

2% more funds holding

Funds holding: 120122 (+2)

Holders
122
Holders Change
+2
Holders Change %
+1.67%
% of All Funds
1.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
21
Increased
41
Reduced
34
Closed
17
Calls
$1.63M
Puts
$351K
Net Calls
+$1.28M
Net Calls Change
+$1.05M
Name Holding Trade Value Shares
Change
Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$1.19M -$2.27K -596 -0.2%
BIP
27
Bouvel Investment Partners
Pennsylvania
$1.13M -$13.1K -3,434 -1%
DRS
28
Deane Retirement Strategies
Louisiana
$1.06M -$2.52K -663 -0.3%
AQR Capital Management
29
AQR Capital Management
Connecticut
$1.05M -$981K -257,722 -51%
Cerity Partners
30
Cerity Partners
New York
$1.04M -$225K -59,132 -19%
QOP
31
Quinn Opportunity Partners
Virginia
$967K
DnB Asset Management
32
DnB Asset Management
Norway
$966K +$865K +227,271 New
UBS Group
33
UBS Group
Switzerland
$944K +$258K +67,865 +44%
IP
34
Intellectus Partners
California
$876K +$62.2K +16,350 +9%
Boston Partners
35
Boston Partners
Massachusetts
$875K -$12K -3,165 -2%
Raymond James Financial
36
Raymond James Financial
Florida
$833K +$746K +195,976 New
JF
37
Jump Financial
Illinois
$794K +$712K +186,929 New
Barclays
38
Barclays
United Kingdom
$763K +$51.2K +13,437 +8%
Charles Schwab
39
Charles Schwab
California
$720K -$2.57K -674 -0.4%
IEFM
40
IQ EQ Fund Management
Ireland
$664K +$419K +110,177 +240%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$598K +$26.8K +7,037 +5%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$589K +$15.7K +4,118 +3%
AGC
43
Aspen Grove Capital
Colorado
$531K
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$481K +$321K +84,379 +294%
Invesco
45
Invesco
Georgia
$477K +$6.01K +1,580 +1%
BFM
46
Boothbay Fund Management
New York
$468K -$381K -99,955 -48%
American Century Companies
47
American Century Companies
Missouri
$467K +$40.8K +10,726 +11%
CCM
48
Connective Capital Management
California
$434K +$389K +102,147 New
SWP
49
Stratos Wealth Partners
Ohio
$332K +$159K +41,720 +115%
GC
50
Guggenheim Capital
Illinois
$322K -$50.6K -13,282 -15%

SRTA Hedge Fund Activity: Q4 2024 in Review

122 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Strata Critical Medical Inc (SRTA) for Q4 2024, worth a combined $184M — up 52% from $121M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new SRTA positions and 17 closed out — a net gain of 4 holders — while 41 added to existing stakes and 34 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $3.17M. The largest seller was Sumitomo Mitsui Trust Group, cutting an estimated $2.51M.

  • 122 institutional investors held Strata Critical Medical Inc (SRTA) as of Q4 2024, up from 120 in Q3 2024.
  • Funds reported $184M of Strata Critical Medical Inc stock for Q4 2024, up 52% quarter-over-quarter.
  • 21 funds opened new Strata Critical Medical Inc positions in Q4 2024 and 17 closed out, a net change of +4 holders.
  • The largest Strata Critical Medical Inc buyer in Q4 2024 was ARK Investment Management, an estimated $3.17M added.
  • The largest Strata Critical Medical Inc seller in Q4 2024 was Sumitomo Mitsui Trust Group, an estimated $2.51M sold.

Based on aggregated 13F filings for Q4 2024.